AnaSpec is pleased to announce the release of a series of zebrafish specific
Z-Fish™ antibodies for use in cell cycle control research. The protein targets
for these antibodies include cyclin D, Rb1 (retinoblastoma associated protein)
and p27 - some of the key players in cell cycle regulation.
Cell proliferation is tightly controlled by cyclin dependent kinases (CDKs)
that function sequentially during cell cycle. These kinases phosphorylate and
thereby regulate key substrates involved in cell cycle progression.1
The regulation of CDKs involves interaction with additional proteins and post-translational
modifications. Essential positive regulators of CDKs are the cyclins, regulatory
subunits of cyclin/CDK kinase complexes that are expressed periodically during
the cell cycle. Furthermore, CDKs are controlled by phosphorylation that either
stimulates or represses catalytic activity.2 CDK inhibitors (CKIs)
have been shown to interact with distinct cyclin/CDK complexes, thereby interfering
with their catalytic activity.3 Induction of the proto-oncogene cyclin
D1, and its binding to CDK4 or CDK6, is a rate-limiting event during cell-cycle
progression through G1 phase. Some studies suggested that cyclin D1 also has
CDK-independent functions.4 Studies in zebrafish model show that
cyclin D1 is upregulated by meis1. Cyclin D1 also controls several development
processes and in some way, carcinogenesis.5 p27KIP1 (p27)
is a CKI that was originally identified as a protein capable of inhibiting G1
cyclin/CDK complexes. p27 was discovered as a protein whose expression is induced
by different growth inhibitory agents, including tumor growth factor beta.6–9
Thus, p27 links proliferative and anti-proliferative signals and controls the
transition from the G1 into the S phase of the cell cycle.
AnaSpec provides 2 anti-cyclin D1 antibodies, one raised with a peptide sequence
from the N-terminus (NT) and the other from the C-terminus (CT). Anti-p27 Kip1
is raised from a C-terminal peptide sequence.
 
The retinoblastoma-associated protein (Rb1) is one of the key cell-cycle regulating
proteins that act as a tumor suppressor. Its
inactivation leads to neoplastic transformation and carcinogenesis. This protein
regulates critical G1-to-S phase transition through interaction with the E2F
family of cell-cycle transcription factors repressing transcription of genes
required for this cell-cycle checkpoint transition.10,11 Its activity
is regulated through network sensing intracellular and extracellular signals
that block or permit phosphorylation (inactivation) of the Rb protein. It also
regulates apoptosis through the same interaction with E2F transcription factors
and Rb–E2F complexes play a role in regulating the transcription of genes involved
in differentiation and development.12,13
| Product |
Cat# |
| Anti
- Rb1 (IN), Z - Fish™ NEW
Retinoblastoma - associated protein
Host: rabbit polyclonal; Application: WB, IHC (predicted) |
55432 |

Related Products:
Z-Fish™ Antibodies for Cell Cycle Control
| Product |
Cat# |
| Anti
- AKT - 3 (CT), Z - Fish™ NEW |
55343 |
| Anti
- AKT - 3 (IN), Z - Fish™ NEW |
55344 |
| Anti
- Bcl - xL (IN), Z - Fish™ NEW
Bcl2 - like protein |
55426 |
| Anti
- Bcl2 (NT), Z - Fish™ NEW |
55396 |
| Anti
- Chk2 (CT), Z - Fish™ NEW |
55435 |
| Anti
- Cyclin D1 (CT), Z - Fish™ NEW |
55400 |
| Anti
- Cyclin D1 (NT), Z - Fish™ NEW |
55399 |
| Anti
- GSK3a (CT), Z - Fish™ NEW
Glycogen synthase kinase 3 alpha |
55397 |
| Anti
- GSK3b (NT), Z - Fish™ NEW
Glycogen synthase kinase 3 alpha |
55424 |
| Anti
- p27 Kip1 (CT), Z - Fish™ NEW
Cyclin - dependent kinase inhibitor 1B (CDKN1B) |
55434 |
| Anti
- p53 (CT), Z - Fish™ NEW |
55342 |
| Anti
- PCNA (IN), Z - Fish™ NEW |
55421 |
| Anti
- PCNA (NT), Z - Fish™ NEW |
55420 |
| Anti
- Rb1 (IN), Z - Fish™ NEW
Retinoblastoma - associated protein |
55432 |
| Anti
- ROCK - 1 (CT), Z - Fish™ NEW
Rho - associated protein kinase 1 |
55430 |
| Anti
- ROCK - 2alpha (CT), Z - Fish™ NEW
Rho - associated protein kinase 2alpha |
55431 |
Z-Fish™ Lysates
Click here
to view a full listing of AnaSpec’s Z-Fish™ antibodies
References
- Nurse, P. Cell 100, 71 (2000).
- Obaya, AJ. and JM. Sedivy, Cell. Mol. Life Sci. 59, 126 (2002).
- Sherr, CJ. and JM. Roberts, Genes Dev. 13, 1501 (1999).
- Fu, M., et al. Endocrinology 145, 5439 (2004).
- Bessa, J. et al. Development 135, 799 (2008).
- Polyak, K. et al. Genes Dev. 8, 9 (1994).
- Polyak, K. et al. Cell 78, 59 (1994).
- Slingerland, JM. et al. Mol. Cell. Biol. 14, 3683 (1994).
- Toyoshima, H. and T. Hunter, Cell 78, 67 (1994).
- Giacinti C and A. Giordano Oncogene 25, 5220 (2006).
- Weinberg, RA. Cell 81, 323 (1995).
- Clarke, AR, et al. Nature (London) 359, 328 (1992).
- Chau, BN and JY. Wang Nat. Rev. Cancer 3, 130 (2003).
|